Prognostic Value of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis of Nodal Involvement, Distant Metastases, Recurrence, and Mortality
Authors' conclusion
Overall, these findings confirm that BRAF V600E mutation is associated with an increased risk of nodal metastasis and recurrence in papillary thyroid carcinoma. However, its lack of impact on distant metastases and disease-specific mortality limits its role as an independent prognostic marker in clinical decision-making.
Study context
- Population
- Patients with PTC; PubMed/MEDLINE, Scopus and Web of Science searched up to August 31, 2025
- Participants
- 20,570 patients46 studies
- Comparison
- BRAF V600E mutation vs no mutation
- Outcome
- Major oncological outcomes: lymph node metastasis, distant metastases, recurrence, cancer-related mortality
Methodological detailsrandom-effects models, PRISMA guidelines, QUADAS-2 quality assessment
- Random-effects models
- PRISMA guidelines
- QUADAS-2 quality assessment
Pooled result
As reported in the abstract
Oncological outcomes by BRAF status
BRAF V600EEstimate (95% CI)
Significant association
OR, lymph node metastasis 1.38(1.17–1.61)
Borderline association
OR, recurrence 1.56(1.00–2.41)
- No significant association with distant metastases
- OR = 0.75; 95% CI, 0.48-1.17
- No significant association with cancer-related mortality
- OR = 0.97; 95% CI, 0.64-1.49
Further pooled results
Sensitivity analyses
- Sensitivity analyses confirmed the robustness of all pooled estimates
Meta-regression
- Inverse relationship between BRAF mutation prevalence and its prognostic impact
Publication bias
- Funnel plot inspection and Egger's tests indicated no major publication bias
Original publication
Prognostic Value of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis of Nodal Involvement, Distant Metastases, Recurrence, and Mortality. Endocr Pract. Published 17 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →